Enumeral to Participate in Immuno-Oncology Panel at the Cantor
Fitzgerald Inaugural Healthcare Conference

July 01, 2015 08:30 AM Eastern Daylight Time

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that
Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of
Enumeral, will participate in a panel discussion, titled “Continued
Opportunities in Immuno-Oncology; Exploring Next-Generation Checkpoint
Inhibition,” at the Cantor Fitzgerald Inaugural Healthcare
Conference, to be held at Le Parker Meridien Hotel in New York City on
Wednesday, July 8, 2015 at 11:15 AM ET.

Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, Tim3, Lag-3, OX40, and VISTA. In developing these agents,
Enumeral’s researchers apply a proprietary immune profiling technology
platform that measures functioning of the human immune system at the
level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.

Recent Stories

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and advancement of nex... more »

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of nov... more »

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of nov... more »